Fact CheckerSign in

NCT03629340CompletedPhase 2

Metformin for Pulmonary Hypertension HFpEF

Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction

Source: ClinicalTrials.gov · Last updated 29 Jun 2026

Brief summary (registry, in English)

The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
33 (actual)
First submitted
10 Aug 2018
Start date
26 Feb 2019
Primary completion date
27 Feb 2026
Lead sponsor
University of California, San Francisco
NCT number
NCT03629340

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 33
  • From 26 Feb 2019 to the primary completion date, 27 Feb 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Currently taking metformin or history of intolerance to metformin or contraindication to taking metformin;

Other illness

  • Uncontrolled systemic hypertension based on repeated measurement of sitting systolic blood pressure \>170 mm Hg or sitting diastolic blood pressure \>95 mm Hg at Screening;
  • Known type 1 diabetes

Lab values

  • Hemoglobin A1C \> 10;
  • Ejection Fraction \< 50%
  • Dementia;
    • 11\. End-stage malignancy; 12. Major cardiovascular event or procedure within 6 weeks prior to enrollment; 13. Severe valvular disease; 14. Other severe acute or chronic medical, psychiatric or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study or would prevent completion of the study; 15. Current Smoker; 16. Hemoglobin \<9 g/dL; 17. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2; 18. Receipt of an investigational product or device, or participation in a drug research study within a period of 15 days 19. \<3 months of stable dose of PDE5i

Age

  • Age less than 18 years;

Other

  • Systemic sitting blood pressure \< 110 mmHg systolic or \< 60 mm Hg diastolic at Screening;
  • Positive urine pregnancy test or breastfeeding

Who the study is looking for

  • 2\. PH-HFpEF Confirmed diagnosis by RHC within the past 6 months:
  • Mean Pulmonary Arterial Pressure (mPAP) ≥ 25 mm Hg AND Pulmonary artery wedge pressure (PAWP) ≥ 15 mm Hg AND Transpulmonary Gradient (TPG) ≥ 12 mm Hg
  • OR Exercise measurements
  • Mean Pulmonary Arterial Pressure (mPAP) ≥ 30 mm Hg AND Pulmonary artery wedge pressure (PAWP) ≥ 20 mm Hg AND PA calculation (change in mPAP/change in cardiac output) = ≥3 mmHg/L/min
  • 3\. Three or more features of metabolic syndrome defined as:
  • Body Mass Index (BMI) ≥ 30 kg/m² Systolic blood pressure (BP) ≥ 130 mm Hg and/or diastolic BP ≥ 85 mm Hg Elevated waist circumference \> 102 cm in men and \> 88 cm in women Fasting triglyceride (TG) level over 150 mg/dl High-density lipoprotein \<40 mg/dL in men or \< 50 mg/dL in women

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Pittsburgh Medical Center
Coordinator of this site? Confirm its status
PittsburghUnited StatesUnknown status
UCSF Medical Center
Coordinator of this site? Confirm its status
San FranciscoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.